Human papillomavirus type 16 viral load is decreased following a therapeutic vaccination

In the dose-escalation phase of a Phase I clinical trial in which six subjects each were vaccinated with PepCan at the 50, 100, 250, and 500 μg per peptide dose, the 50 μg dose showed the best histological regression rate. Ten additional subjects were vaccinated at this dose in the final dose phase....

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cancer Immunol Immunother
Hlavní autoři: Coleman, Hannah N., Greenfield, William W., Stratton, Shawna L., Vaughn, Rita, Kieber, Alexander, Moerman-Herzog, Andrea M., Spencer, Horace J., Hitt, Wilbur. C., Quick, Charles Matthew, Hutchins, Laura F., Mackintosh, Samuel G., Edmondson, Ricky D., Erickson, Stephen W., Nakagawa, Mayumi
Médium: Artigo
Jazyk:Inglês
Vydáno: Springer Berlin Heidelberg 2016
Témata:
Original Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4841729/
https://ncbi.nlm.nih.gov/pubmed/26980480
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00262-016-1821-x
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky